Solid Tumor
Conditions
Brief summary
TQB3811 tablet is a second-generation tropomyosin receptor kinase (TRK) inhibitor that selectively inhibits the kinase activity of TRKA, TRKB, and TRKC, and also selectively inhibits the kinase activity of TRKA, TRKB, and TRKC that produce secondary drug-resistant mutations.
Interventions
DRUGTQB3811
TQB3811 is a second-generation TrkA inhibitor.
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with advanced malignancy diagnosed histologically and/or cytologically, who have failed standard treatment or are unable to receive standard treatment or have no effective treatment. * Age: 18\ 75 years old. * Women of childbearing age must be negative for serum or urine HCG within 7 days prior to study enrollment and must be non-lactating; Patients should agree to use contraception during the study period and for 6 months after the study period. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months. * Patients voluntarily joined the study and signed the informed consent, showing good compliance.
Exclusion criteria
* Patients has had or is currently having other malignant tumors within 3 years. * Patients have multiple factors that affect their oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction). * The patient had unmitigated toxic reactions due to any prior treatment. * Patients underwent major surgical treatment, open biopsy, or significant traumatic injury within 4 weeks prior to the start of study treatment. * Patients have long-term unhealed wounds or fractures. * The patient had experienced an arterial/venous thrombosis event in the past 6 months, such as a cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism. * The patient has a history of psychotropic drug abuse and cannot quit or has mental disorders. * Patients are taking cytochrome P450 3A (CYP3A) inhibitors or inducers. * Patients have uncontrolled pleural effusion, pericardial effusion, or ascites that still require repeated drainage. * Patients with brain metastases with symptoms or control of symptoms for less than 2 weeks. * The patients were currently breastfeeding or planned to breastfeed during the study period. * Patients who, in the investigator's judgment, have a comorbidity that seriously endangers patient safety or interferes with study completion, or who are considered unsuitable for inclusion for other reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) | Baseline up to 32 weeks | To evaluate MTD of TQB3811 tablets in Chinese adult patients with advanced solid tumors |
| Adverse events (AEs) and serious adverse events (SAEs) | Baseline up to 28 days | The occurrence of all AEs and SAEs |
| Dose-limiting toxicity (DLT) | Baseline up to 32 weeks | To evaluate DLT of TQB3811 tablets in Chinese adult patients with advanced solid tumors |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration-time curve from time zero to time t （AUC0-t） | 15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 ;30 minutes before oral administration on day 1. | To characterize the pharmacokinetics of TQB3811 by assessment of area under the plasma concentration time curve from the first dose to infinity. |
| Maximum (peak) steady-state plasma drug concentration during a dosage interval （Cmax,ss） | 15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11. | Cmax,ss is maximum (peak) steady-state plasma drug concentration during a dosage interval . |
| Minimum steady-state plasma drug concentration during a dosage interval （Css-min） | 15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11. | Css-min is minimum steady-state plasma drug concentration during a dosage interval. |
| Time to reach maximum (peak) plasma concentration following drug administration（Tmax） | 15, 30minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11. | To characterize the pharmacokinetics of TQB3811 by assessment of time to reach maximum plasma concentration after single and multiple dosing |
| Progress Free Survival（PFS） | up to 96 weeks | From the start of randomization to the first tumor progression or time of death. |
| Disease control rate（DCR） | up to 96 weeks | Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD). |
| Duration of Response (DOR) | up to 96 weeks | The time when the participants first achieved complete or partial remission to disease progression. |
| Concentration at the end of the dosing interval (AUCtau,ss) | 15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11. | To characterize the pharmacokinetics of TQB3811 by assessment of area The concentration at the end of the administration interval |
| Maximum (peak) plasma drug concentration （Cmax） | 15, 30 minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 ;30 minutes before oral administration on day 1. | Cmax is the maximum plasma concentration of TQB3811 or metabolite(s). |
| Elimination half-life （t1/2） | 15, 30minutes, 1, 2, 4, 6, 8,10, 24, 48 hours after oral administration of day 1 and day 11;30 minutes before oral administration on day 1, day5, day7,day8 ,day 9 and day11. | t1/2 is time it takes for the blood concentration of TQB3811 or metabolite(s) to drop by half. |
Countries
China
Contacts
Primary ContactLIN SHEN, Master
Outcome results
None listed